BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

269 related articles for article (PubMed ID: 21048198)

  • 1. Novel CSF biomarkers for frontotemporal lobar degenerations.
    Hu WT; Chen-Plotkin A; Grossman M; Arnold SE; Clark CM; Shaw LM; McCluskey L; Elman L; Hurtig HI; Siderowf A; Lee VM; Soares H; Trojanowski JQ
    Neurology; 2010 Dec; 75(23):2079-86. PubMed ID: 21048198
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ante mortem cerebrospinal fluid tau levels correlate with postmortem tau pathology in frontotemporal lobar degeneration.
    Irwin DJ; Lleó A; Xie SX; McMillan CT; Wolk DA; Lee EB; Van Deerlin VM; Shaw LM; Trojanowski JQ; Grossman M
    Ann Neurol; 2017 Aug; 82(2):247-258. PubMed ID: 28719018
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A 2-Step Cerebrospinal Algorithm for the Selection of Frontotemporal Lobar Degeneration Subtypes.
    Lleó A; Irwin DJ; Illán-Gala I; McMillan CT; Wolk DA; Lee EB; Van Deerlin VM; Shaw LM; Trojanowski JQ; Grossman M
    JAMA Neurol; 2018 Jun; 75(6):738-745. PubMed ID: 29554190
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reduced CSF p-Tau181 to Tau ratio is a biomarker for FTLD-TDP.
    Hu WT; Watts K; Grossman M; Glass J; Lah JJ; Hales C; Shelnutt M; Van Deerlin V; Trojanowski JQ; Levey AI
    Neurology; 2013 Nov; 81(22):1945-52. PubMed ID: 24174584
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Elevated YKL-40 and low sAPPβ:YKL-40 ratio in antemortem cerebrospinal fluid of patients with pathologically confirmed FTLD.
    Alcolea D; Irwin DJ; Illán-Gala I; Muñoz L; Clarimón J; McMillan CT; Fortea J; Blesa R; Lee EB; Trojanowski JQ; Grossman M; Lleó A
    J Neurol Neurosurg Psychiatry; 2019 Feb; 90(2):180-186. PubMed ID: 30297518
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cerebrospinal Fluid Biomarkers in Patients with Frontotemporal Dementia Spectrum: A Single-Center Study.
    Abu-Rumeileh S; Mometto N; Bartoletti-Stella A; Polischi B; Oppi F; Poda R; Stanzani-Maserati M; Cortelli P; Liguori R; Capellari S; Parchi P
    J Alzheimers Dis; 2018; 66(2):551-563. PubMed ID: 30320576
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tau Rather than TDP-43 Proteins are Potential Cerebrospinal Fluid Biomarkers for Frontotemporal Lobar Degeneration Subtypes: A Pilot Study.
    Kuiperij HB; Versleijen AA; Beenes M; Verwey NA; Benussi L; Paterlini A; Binetti G; Teunissen CE; Raaphorst J; Schelhaas HJ; Küsters B; Pijnenburg YA; Ghidoni R; Verbeek MM
    J Alzheimers Dis; 2017; 55(2):585-595. PubMed ID: 27662293
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Multimarker synaptic protein cerebrospinal fluid panels reflect TDP-43 pathology and cognitive performance in a pathological cohort of frontotemporal lobar degeneration.
    Cervantes González A; Irwin DJ; Alcolea D; McMillan CT; Chen-Plotkin A; Wolk D; Sirisi S; Dols-Icardo O; Querol-Vilaseca M; Illán-Gala I; Santos-Santos MA; Fortea J; Lee EB; Trojanowski JQ; Grossman M; Lleó A; Belbin O
    Mol Neurodegener; 2022 Apr; 17(1):29. PubMed ID: 35395770
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Frontotemporal lobar degeneration proteinopathies have disparate microscopic patterns of white and grey matter pathology.
    Giannini LAA; Peterson C; Ohm D; Xie SX; McMillan CT; Raskovsky K; Massimo L; Suh E; Van Deerlin VM; Wolk DA; Trojanowski JQ; Lee EB; Grossman M; Irwin DJ
    Acta Neuropathol Commun; 2021 Feb; 9(1):30. PubMed ID: 33622418
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sex Hormone-Binding Globulin (SHBG) in Cerebrospinal Fluid Does Not Discriminate between the Main FTLD Pathological Subtypes but Correlates with Cognitive Decline in FTLD Tauopathies.
    Campo MD; Pijnenburg YAL; Chen-Plotkin A; Irwin DJ; Grossman M; Twaalfhoven HAM; Hu WT; Meeter LH; van Swieten J; Vermunt L; Martens F; Heijboer AC; Teunissen CE
    Biomolecules; 2021 Oct; 11(10):. PubMed ID: 34680117
    [TBL] [Abstract][Full Text] [Related]  

  • 11. White matter imaging helps dissociate tau from TDP-43 in frontotemporal lobar degeneration.
    McMillan CT; Irwin DJ; Avants BB; Powers J; Cook PA; Toledo JB; McCarty Wood E; Van Deerlin VM; Lee VM; Trojanowski JQ; Grossman M
    J Neurol Neurosurg Psychiatry; 2013 Sep; 84(9):949-55. PubMed ID: 23475817
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Concurrent tau pathologies in frontotemporal lobar degeneration with TDP-43 pathology.
    Koga S; Zhou X; Murakami A; Fernandez De Castro C; Baker MC; Rademakers R; Dickson DW
    Neuropathol Appl Neurobiol; 2022 Feb; 48(2):e12778. PubMed ID: 34823271
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Apolipoprotein L1 is increased in frontotemporal lobar degeneration post-mortem brain but not in ante-mortem cerebrospinal fluid.
    Hok-A-Hin YS; Dijkstra AA; Rábano A; Hoozemans JJ; Castillo L; Seelaar H; van Swieten JC; Pijnenburg YAL; Teunissen CE; Del Campo M
    Neurobiol Dis; 2022 Oct; 172():105813. PubMed ID: 35820647
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cerebrospinal fluid Aβ40 is similarly reduced in patients with Frontotemporal Lobar Degeneration and Alzheimer's Disease.
    Baldeiras I; Santana I; Leitão MJ; Ribeiro MH; Pascoal R; Duro D; Lemos R; Santiago B; Almeida MR; Oliveira CR
    J Neurol Sci; 2015 Nov; 358(1-2):308-16. PubMed ID: 26388316
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CSF sAPPβ, YKL-40, and neurofilament light in frontotemporal lobar degeneration.
    Alcolea D; Vilaplana E; Suárez-Calvet M; Illán-Gala I; Blesa R; Clarimón J; Lladó A; Sánchez-Valle R; Molinuevo JL; García-Ribas G; Compta Y; Martí MJ; Piñol-Ripoll G; Amer-Ferrer G; Noguera A; García-Martín A; Fortea J; Lleó A
    Neurology; 2017 Jul; 89(2):178-188. PubMed ID: 28592456
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Diagnostic value of cerebrospinal fluid tau, neurofilament, and progranulin in definite frontotemporal lobar degeneration.
    Goossens J; Bjerke M; Van Mossevelde S; Van den Bossche T; Goeman J; De Vil B; Sieben A; Martin JJ; Cras P; De Deyn PP; Van Broeckhoven C; van der Zee J; Engelborghs S
    Alzheimers Res Ther; 2018 Mar; 10(1):31. PubMed ID: 29559004
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Distinguishing Frontotemporal Lobar Degeneration Tau From TDP-43 Using Plasma Biomarkers.
    Cousins KAQ; Shaw LM; Chen-Plotkin A; Wolk DA; Van Deerlin VM; Lee EB; McMillan CT; Grossman M; Irwin DJ
    JAMA Neurol; 2022 Nov; 79(11):1155-1164. PubMed ID: 36215050
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Searching for novel cerebrospinal fluid biomarkers of tau pathology in frontotemporal dementia: an elusive quest.
    Foiani MS; Cicognola C; Ermann N; Woollacott IOC; Heller C; Heslegrave AJ; Keshavan A; Paterson RW; Ye K; Kornhuber J; Fox NC; Schott JM; Warren JD; Lewczuk P; Zetterberg H; Blennow K; Höglund K; Rohrer JD
    J Neurol Neurosurg Psychiatry; 2019 Jul; 90(7):740-746. PubMed ID: 30981993
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Csf p-tau181/tau ratio as biomarker for TDP pathology in frontotemporal dementia.
    Borroni B; Benussi A; Archetti S; Galimberti D; Parnetti L; Nacmias B; Sorbi S; Scarpini E; Padovani A
    Amyotroph Lateral Scler Frontotemporal Degener; 2015 Mar; 16(1-2):86-91. PubMed ID: 25352065
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CSF biomarkers in frontotemporal lobar degeneration with known pathology.
    Bian H; Van Swieten JC; Leight S; Massimo L; Wood E; Forman M; Moore P; de Koning I; Clark CM; Rosso S; Trojanowski J; Lee VM; Grossman M
    Neurology; 2008 May; 70(19 Pt 2):1827-35. PubMed ID: 18458217
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.